{"meta":{"query_hash":"37f195c477b7","filters":{"venue":"Leukemia Supplements"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/37f195c477b7","api":"https://metacan.xera.ac/api/v1/cohort?venue=Leukemia+Supplements"},"results":[{"id":"W2051100871","doi":"10.1038/leusup.2013.4","title":"Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation","year":2013,"lang":"en","type":"review","venue":"Leukemia Supplements","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Celgene","keywords":"Bortezomib; Medicine; Thalidomide; Multiple myeloma; Lenalidomide; Dexamethasone; Regimen; Oncology; Maintenance therapy; Autologous stem-cell transplantation; Transplantation; Internal medicine; Cyclophosphamide; Surgery; Chemotherapy","score_opus":0.045305924193648706,"score_gpt":0.35126087339167766,"score_spread":0.30595494919802896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051100871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030956505,0.99909735,0.000023057426,0.00022714646,0.00005151172,0.0000041567837,0.000027569558,0.000001737624,0.00025792263],"genre_scores_gemma":[0.0033511296,0.9958112,0.0001674746,0.00037458693,0.00008695082,0.000011017951,0.000053350184,7.473296e-7,0.00014346722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977,0.000058009202,0.00006289889,0.00003528369,0.000051933053,0.000021826829],"domain_scores_gemma":[0.99940276,0.00035413352,0.0001575568,0.000006297778,0.000056469693,0.000022894392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061705563,0.0006107166,0.001868109,0.0010753573,0.00018949396,0.00052149483,0.0005270462,0.0006607119,0.0031764854],"category_scores_gemma":[0.0020288804,0.0001662365,0.0013422448,0.0012138278,0.00016833849,0.00046653685,0.00044411994,0.0011657131,0.0002249897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060277217,0.00012981327,0.0015952145,0.06371848,0.0017116683,0.00008650389,0.00004409805,0.00029355654,0.0003133344,0.0008133829,0.017558342,0.91313285],"study_design_scores_gemma":[0.0020781553,0.0012835835,0.03388802,0.18409751,0.02767162,0.0020633067,0.00048156347,0.00055264967,0.0010452481,0.0047077094,0.74202555,0.00010515175],"about_ca_topic_score_codex":0.0028001415,"about_ca_topic_score_gemma":0.0086939465,"teacher_disagreement_score":0.0031764854,"about_ca_system_score_codex":0.0006994965,"about_ca_system_score_gemma":0.0012764065,"threshold_uncertainty_score":0.010626376},"labels":[],"label_agreement":null},{"id":"W2093253247","doi":"10.1038/leusup.2014.3","title":"STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia Supplements","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; Brown University; Celgene; Gilead Sciences; Bristol-Myers Squibb","keywords":"Dasatinib; Nilotinib; Myeloid leukemia; Medicine; Cancer research; Imatinib mesylate; Imatinib; Tyrosine kinase; Leukemia; Immunology; Myeloid; Tyrosine-kinase inhibitor; Internal medicine; Cancer; Receptor","score_opus":0.010311575729924442,"score_gpt":0.272663253366069,"score_spread":0.2623516776361446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093253247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595712,0.021875994,0.0008483166,0.0016539865,0.00021866732,0.0000815666,0.00079400325,0.00015622919,0.014799985],"genre_scores_gemma":[0.9925067,0.0034417168,0.0004013268,0.00019852504,0.000044556262,0.000017428178,0.00045377918,0.000010203345,0.002925702],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990237,0.000021540012,0.000006268292,0.0000074551403,0.000031800028,0.000030438488],"domain_scores_gemma":[0.9999527,0.000009447367,0.0000132016075,0.0000056068366,0.000007143983,0.000011861459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021366781,0.00018651312,0.00026400617,0.0002800817,0.00024207144,0.000457893,0.00024306825,0.0002749368,0.0035531656],"category_scores_gemma":[0.0001475364,0.00008554498,0.00023946256,0.00027104322,0.00019989317,0.0001865581,0.00023003074,0.0006538657,0.00048248027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009487245,0.0011292145,0.0041523734,0.0006716175,0.00015038054,0.00050745497,0.00012462062,0.0011064605,0.83345574,0.0062374147,0.0071520153,0.13582544],"study_design_scores_gemma":[0.0036668286,0.008590574,0.0852575,0.00017153077,0.00058290234,0.0026663241,0.0005386875,0.0050895815,0.7594094,0.004790544,0.1291783,0.000057780413],"about_ca_topic_score_codex":0.0007774501,"about_ca_topic_score_gemma":0.0020207672,"teacher_disagreement_score":0.0035531656,"about_ca_system_score_codex":0.0004819868,"about_ca_system_score_gemma":0.00042377264,"threshold_uncertainty_score":0.0118864775},"labels":[],"label_agreement":null}]}